

# Thesis Proposal

## Predictive Modeling with Imbalanced Data

*Alyssa Forber*

*Susan Calcaterra, Elizabeth Juarez-Colunga, Kathryn Colborn*

*February 07, 2018*

## Introduction

The misuse of opioids has become an increasing problem in the United States. The number of opioid related overdose deaths has continued to increase, and deaths from pre-scripted opioids have more than quadrupled since 1997.<sup>1</sup> In 2015 alone there were 20,101 overdose deaths related to prescription opioids and 12,990 overdose deaths related to heroin.<sup>2</sup> Due to all this, the need to identify patients at increase risk for opioid abuse is immediate.

\*\*Need to differentiate between opioid addiction and chronic opioid therapy– we are looking at COT and need to explain why that is important \*Mention “adhered to the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) statement on reporting predictive models.”

This issue now presents a statistical problem, as this is a rare outcome which makes prediction more challenging. Predictive modeling with imbalanced data has been found to report low sensitivity. Many people have tried to combat this issue in the past. Other researches have attempted to fix the issue of over fitting with shrinkage methods like ridge regression or lasso<sup>3</sup>, random forests<sup>4</sup>, as well as many sampling techniques<sup>5</sup> and adjusting probability cut-points.<sup>6</sup> However, no one has yet explored the trade offs of probability cut-points and sampling methods, which is what we desired to do in this analysis to achieve the best prediction. We sought to identify patients at risk for chronic opioid therapy using

---

<sup>1</sup>CDC. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at <http://wonder.cdc.gov>.

<sup>2</sup>Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016;65:1445–1452. DOI: <http://dx.doi.org/10.15585/mmwr.mm6505051e1>.

<sup>3</sup>Pavlou Menelaos, Ambler Gareth, Seaman Shaun R, Guttman Oliver, Elliott Perry, King Michael et al. How to develop a more accurate risk prediction model when there are few events BMJ 2015; 351 :h3868

<sup>4</sup>Khalilia, M., et al. (2011). “Predicting disease risks from highly imbalanced data using random forest.” BMC Med Inform Decis Mak 11: 51.

<sup>5</sup>Yap B.W., et al. (2014) An Application of Oversampling, Undersampling, Bagging and Boosting in Handling Imbalanced Datasets. Proceedings of the First International Conference on Advanced Data and Information Engineering (DaEng-2013). Lecture Notes in Electrical Engineering, vol 285. Springer, Singapore

<sup>6</sup>D.E. Amrine, B.J. White, R.L. Larson Comparison of classification algorithms to predict outcomes of feedlot cattle identified and treated for bovine respiratory disease Comput. Electron. Agri., 105 (2014), pp. 9-19

several different approaches to optimize probability cut-points and sample the data in order to compare and contrast the predictive performance of these imbalanced data techniques.

## Methods

### Data

To illustrate this issue, we are using electronic health record data from Denver Health from the years 2008 to 2014 of patients for patients with chronic opioid therapy (COT). This is an urban, safety-net hospital. Five percent of the 27,705 patients were reported with the outcome, which was defined as receipt of  $\geq 90$ -day supply of opioids with  $< 30$ -day gap in supply over a 180-day period or receipt of  $\geq 10$  opioid prescriptions over one year. The data also contained demographic information on the patient including age, race, gender, history of chronic pain, and length of hospital stay.

### Statistical Methods

The analysis was done in RStudio version 1.1.383. We used a roughly 2/3rd temporal split of the data to create training and testing datasets, where years 2008-2011 were used to train (65%), and 2012-2014 were used to test (35%). The predictors were narrowed from 50 to 35 based on clinical relevance. The model used for this analysis was cross validated lasso regression.<sup>78</sup> This was chosen as it has been found to perform better predictor selection than stepwise selection, and as we were not interested in having interpretable coefficients.

As a comparison, we first evaluated the prediction performance of the dataset without sampling to see the effects of the imbalanced data on the accuracy, sensitivity, and specificity. This was to serve as a baseline to compare with the techniques available to mitigate the issue of poor sensitivity. The predicted probability cut-point used here was rounding at the standard 0.5 that would be appropriate in balanced datasets.

The first approach used to improve performance was choosing a more informed probability cut-point for the data. This was done using the Youden Index<sup>9</sup>, which finds the maximum of the receiver operating characteristic (ROC) curve<sup>10</sup> with the pROC package. The second approach was through sampling the dataset. Three types of sampling methods were compared—down sampling, up sampling, and Synthetic Minority Over-sampling Technique (SMOTE)<sup>11</sup>. Down sampling takes a random sample from the majority class, in this case those who are

---

<sup>7</sup>Browne, M. W. (2000). “Cross-validation methods.” *Journal of Mathematical Psychology* 44(1): 108-132.

<sup>8</sup>Tibshirani, R. (1996). Regression Shrinkage and Selection via the Lasso. *J. Roy. Stat. Soc. Ser. B*, 58(1), 267–288.

<sup>9</sup>Fluss, R., et al. (2005). “Estimation of the Youden Index and its associated cutoff point.” *Biom J* 47(4): 458-472.

<sup>10</sup>Zou, K. H., et al. (2007). “Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models.” *Circulation* 115(5): 654-657.

<sup>11</sup>Nakamura, M., et al. (2013). “LVQ-SMOTE - Learning Vector Quantization based Synthetic Minority Over-sampling Technique for biomedical data.” *BioData Min* 6(1): 16.

not classified as having chronic opioid therapy, in order to match the size of the minority class. Up sampling does the reverse to take random samples of the minority class in order to match the majority. SMOTE combines sampling both from the majority and minority, but instead of taking identical copies of the minority it creates synthetic observations using nearest neighbors. For each of the three sampling techniques, the standard 0.5 probability cut-point was used, and the cut-point was optimized using the Youden Index for comparison.

## Results

As expected, without using an optimized cut-point or sampling technique, the sensitivity of the model was extremely poor at 8%, with high specificity and accuracy (99% and 96%). Simply choosing a more informed probability cut-point at 0.043 instead of 0.5 improved the sensitivity to 85% and brought the specificity down to 73%. This cut-point is intuitive as the outcome is present at 5% in the dataset, which would be consistent with a 0.5 cutoff in a evenly split dataset. The up and down sampled datasets both showed the same improved sensitivity with Youden index for probability cut-points at about 0.4, also with close specificities of 74 and 73%. SMOTE on the other hand, resulted in 74% sensitivity and 84% specificity. However, there were improvements in accuracy for SMOTE at 86% as compared to the other three approaches, which had accuracies at 86-87%. When using the standard 0.5 cut-point for up and down sampling, the accuracy improved from 74% to 82 and 81%, while the values for sensitivity and specificity stayed high but reversed in magnitude with specificities in the 70 percent range and sensitivities in the 80s.

There was no change to the negative predicted value across the approaches, and a decrease in positive predicted value. In terms of the ROC analysis, the area under the curve for each approach was about the same at 86-87%. See Table 1 for full results for the cut-point, sensitivity, specificity, accuracy, negative predicted value, positive predicted value, and area under the curve.

## Conclusions

Both sampling and optimizing probability cutpoints, alone and combined, improved the predicted sensitivity drastically. There was not a distinguishable difference between over and under sampling for either approach, while the SMOTE algorithm appeared to give lower sensitivity than the other two sampling techniques. In addition, using the Youden index resulted in very similar results as to when the Youden index was used in conjunction with sampling. This may suggest that using both sampling and an informed cut-point at the same time is not necessary, since equivalent predictive performance is seen with the Youden index alone.

Moreover, the decision as to what approach to use is largely influenced by the circumstances of the problem. In some cases it may be more important to have a higher sensitivity than specificity, or vice versa. It may come down to the clinician's decision to have a threshold

Table 1: Results

Data	Threshold	Specificity	Sensitivity	NPV	PPV	Accuracy	AUC	Covariates
Unsampled 0.5	0.5	99	8	96	35	96	86	31
Unsampled	0.043	73	85	99	12	73	86	31
Down sampled 0.5	0.5	81	75	99	15	81	86	34
Down sampled	0.401	73	85	99	12	74	86	34
Up sampled 0.5	0.5	82	75	99	15	82	87	34
Up sampled	0.399	74	85	99	12	74	87	34
SMOTE 0.5	0.5	86	71	99	17	85	86	33
SMOTE	0.472	84	74	99	17	84	86	33




Figure 1: ROC for Unsampled Data: Younden and 0.5 cutoffs

of sensitivity that is needed. As it can be a case by case choice with many trade offs, no one method is recommended above the others.

To expand upon this analysis, we plan to implement a simulation that explores predictive performance of these models at different rarities for the outcome. This is to get a better idea of how they perform in other circumstances as well as see when these techniques are no longer needed because the imbalance does not affect model performance. We also plan to implement bootstrap aggregating, also known as bagging. This model averaging approach will hopefully improve the stability and accuracy of our models. Lastly, other sampling or optimized probability cut-point techniques that are found to be promising may be incorporated into the analysis.

## Appendix

	Chronic Opioid Use			P- Value
	Total (N=27,705)	Yes (N=1,457)	No (N=26,248)	
Gender, n (%)				
Female	12,933 (46.7)	652 (44.7)	12,281 (46.8)	0.13
Race, n (%)				
Hispanic	10,798 (39.0)	580 (39.8)	10,218 (38.9)	0.01
Non-Hispanic White	10,645 (38.4)	555 (38.1)	10,090 (38.4)	
African American	4,842 (17.5)	273 (18.7)	4,569 (17.4)	
Other or Unknown	1,420 (5.1)	49 (3.4)	1,371 (5.2)	
Age at Index Admission (Years), n (%)				
15-<35	6,017 (21.7)	150 (10.3)	5,867 (22.4)	<0.0001
35-<45	4,734 (17.1)	267 (18.3)	4,467 (17.0)	
45-<55	6,919 (25.0)	506 (34.7)	6,413 (24.4)	
55-<65	5,880 (21.2)	400 (27.5)	5,480 (20.9)	
65-<75	2,745 (9.9)	110 (7.5)	2,635 (10)	
75-185	1,410 (5.1)	24 (1.6)	1,386 (5.3)	
Mean (SD)	48.1 (16.0)	50.2 (11.6)	48.0 (16.2)	
Median (25th, 75th)	49 (37, 59)	51 (43, 58)	49 (36, 59)	
Insurance Status, n (%)				
Discount Payment Plan*	8,499 (30.7)	576 (39.5)	7,923 (30.2)	<0.0001
Medicaid	8,575 (31.0)	531 (36.4)	8,044 (30.6)	
Medicare	6,260 (22.6)	259 (17.8)	6,001 (22.9)	

		Chronic Opioid Use		P- Value
Commercial	2,402 (8.7)	50 (3.4)	2,352 (9.0)	
Other/Unknown/Self-Pay	1,969 (7.1)	41 (2.8)	1,928 (7.3)	
Three Year History of, n (%)				
Tobacco Use Disorder	9,682 (34.9)	716 (49.1)	8,966 (34.2)	<0.0001
Alcohol Use Disorder	7,167 (25.9)	408 (28.0)	6,759 (25.8)	0.06
Stimulant Use Disorder	1,719 (6.2)	118 (8.1)	1,601 (6.1)	0.003
Opioid Use Disorder	672 (2.4)	44 (3.0)	628 (2.4)	0.13
Chronic Pain	14,914 (53.8)	1,105 (75.8)	13,809 (52.6)	<0.0001
Acute Pain	10,073 (36.4)	611 (41.9)	9,462 (36.0)	<0.0001
Top 3 Mental Health Disorders, n (%)				
Depression	6,318 (22.8)	491 (33.7)	5,827 (22.2)	<0.0001
Anxiety Disorder	3,677 (13.3)	265 (18.2)	3,412 (13.0)	<0.0001
Bipolar Disorder	2,362 (8.5)	135 (9.3)	2,227 (8.5)	0.3
Any Mental Health Disorder n (%)	9,805 (35.4)	634 (43.5)	9,171 (34.9)	<0.0001
Top 3 Chronic Medical Conditions, n (%)				
Hypertension	11,799 (42.6)	773 (53.1)	11,026 (42.0)	<0.0001
Respiratory Disease	7,060 (25.5)	444 (30.5)	6,616 (25.2)	<0.0001
Diabetes Mellitus	5,701 (20.6)	376 (25.8)	5,325 (20.3)	<0.0001
Any Chronic Medical Condition, n (%)	17,535 (63.3)	1,102 (75.6)	16,433 (62.6)	<0.0001
Charlson Comorbidity Index from 3 Year Diagnosis History				

		Chronic Opioid Use		P- Value
Mean (SD)	1.9 (2.2)	2.4 (2.5)	1.9 (2.2)	<0.0001
Median (25th, 75th)	1 (0, 3)	2.0 (1, 3)	1.0 (0, 3)	
Discharge Diagnoses, n (%)				
Chronic Pain__	8,346 (30.1)	729 (50.0)	7,617 (29.0)	<0.0001
Acute Painr	4,586 (16.6)	255 (17.5)	4,331 (16.5)	0.32
Neoplasmx	1,447 (5.2)	170 (11.7)	1,277 (4.9)	<0.0001
Top 3 Surgical Procedures During Initial Hospitalization, n (%)				
Digestive System	3,437 (12.4)	225 (15.4)	3,212 (12.2)	<0.001
Musculoskeletal System	3,037 (11.0)	258 (17.7)	2,779 (10.6)	<0.0001
Cardiovascular System	2,312 (8.3)	157 (10.8)	2,155 (8.2)	<0.001
Patients Who Had Surgical Procedure During Index Hospitalization, n (%)	10,956 (39.5)	700 (48.0)	10,256 (39.1)	<0.0001
Number of Healthcare Encounters in the One Year Preceding the Index Admission, n (%)				
0	23,280 (84.0)	1,196 (82.1)	22,084 (84.1)	0.03
1	3,413 (12.3)	197 (13.5)	3,216 (12.3)	
2+	1,012 (3.7)	64 (4.4)	948 (3.6)	
Mean (SD)	0.2 (0.6)	0.2 (0.7)	0.2 (0.6)	
Median (25th, 75th)	0.0 (0, 0)	0.0 (0, 0)	0.0 (0, 0)	
Past Year Benzodiazepine Receipt, n (%)	1,606 (5.8)	227 (15.6)	1,379 (5.3)	<0.0001
Past Year Receipt of Non-Opioid Analgesics (NSAIDs, neuropathic agents, topical capsaicin & lidocaine), n (%)	4,875 (17.6)	620 (42.6)	4,255 (16.2)	<0.0001
Past Year Number of Opioid Prescriptions Filled, n (%)				

		Chronic Opioid Use		P- Value
0	21,543 (77.8)	549 (37.7)	20,994 (80.0)	<0.0001
1	3,167 (11.7)	249 (17.1)	2,918 (11.1)	
2	1,331 (4.8)	197 (13.5)	1,134 (4.3)	
3	646 (2.3)	132 (9.1)	514 (2.0)	<0.0001
9-Apr	1,018 (3.7)	330 (22.6)	688 (2.6)	
Receipt of Opioid at Discharge, n (%)	8,028 (29.0)	817 (56.1)	7,211 (27.5)	
Milligrams of Morphine Per Hospital Day, n (%)				
0	9,655 (34.8)	189 (13.0)	9,466 (36.1)	<0.0001
0.01 < 10	3,320 (12.0)	108 (7.4)	3,212 (12.2)	
10 < 51	7,337 (26.5)	490 (33.6)	6,847 (26.1)	
51 < 100	4,413 (15.)	371 (25.5)	4,042 (15.4)	
100+	2,980 (10.8%)	299 (20.5)	2,681 (10.2)	
Mean (SD)	37.7 (65.4)	64.4 (76.7)	36.2 (64.4)	
Median (25th, 75th)	12.5 (0, 54.7)	45.5 (14.3, 90.2)	10.8 (0, 52.2)	
Length of Hospital Stay (days)				
1	8,449 (30.0)	383 (26.3)	8,066 (30.7)	0.0003
2	5,655 (20.4)	282 (19.4)	5,373 (20.5)	
5-Mar	7,801 (28.2)	450 (30.9)	7,351 (28.0)	
6+	5,800 (20.9)	342 (23.5)	5,458 (20.8)	
Mean (SD)	4.7 (9.0)	4.9 (7.7)	4.6 (9.1)	
Median (25th, 75th)	2 (1, 5)	3 (1, 5)	2 (1, 5)	



		Chronic Opioid Use		P- Value
Number of Subsequent Hospitalizations within 12 Months post Hospital Discharge				<0.001
Mean (SD)	NA	1.48 (2.20)	0.54 (1.21)	
Median (25th, 75th)	NA	1 (0,2)	0 (0,1)	